Brokerages Set Galapagos NV (NASDAQ:GLPG) Target Price at $26.75

Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have received a consensus recommendation of "Strong Sell" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $26.75.

Several research firms have commented on GLPG. Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and cut their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. TD Cowen cut shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Barclays reaffirmed an "underweight" rating on shares of Galapagos in a research report on Thursday, January 23rd. Finally, Kepler Capital Markets cut shares of Galapagos from a "hold" rating to a "reduce" rating in a research report on Wednesday, November 20th.

Galapagos Trading Up 0.1 %

Shares of NASDAQ:GLPG traded up $0.03 during midday trading on Tuesday, reaching $26.58. 187,592 shares of the company were exchanged, compared to its average volume of 301,073. Galapagos has a fifty-two week low of $22.36 and a fifty-two week high of $35.06. The stock has a fifty day simple moving average of $25.29 and a two-hundred day simple moving average of $27.14.

Remove Ads

Institutional Investors Weigh In On Galapagos

Institutional investors and hedge funds have recently modified their holdings of the company. R Squared Ltd bought a new stake in Galapagos in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC lifted its holdings in Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 974 shares during the last quarter. QRG Capital Management Inc. bought a new position in Galapagos during the third quarter worth $247,000. BNP Paribas Financial Markets increased its holdings in shares of Galapagos by 45.9% in the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of Galapagos in the third quarter valued at about $410,000. 32.46% of the stock is owned by institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.